In the past week, ITCI stock has gone up by 0.21%, with a monthly gain of 2.79% and a quarterly surge of 58.41%. The volatility ratio for the week is 0.12%, and the volatility levels for the last 30 days are 0.21% for Intra-Cellular Therapies Inc The simple moving average for the past 20 days is 0.93% for ITCI’s stock, with a 46.97% simple moving average for the past 200 days.
Is It Worth Investing in Intra-Cellular Therapies Inc (NASDAQ: ITCI) Right Now?
Company’s 36-month beta value is 0.46.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for ITCI is 98.88M, and currently, short sellers hold a 2.36% ratio of that floaft. The average trading volume of ITCI on March 19, 2025 was 3.12M shares.
ITCI) stock’s latest price update
Intra-Cellular Therapies Inc (NASDAQ: ITCI)’s stock price has soared by 0.06 in relation to previous closing price of 131.45. Nevertheless, the company has seen a gain of 0.21% in its stock price over the last five trading days. businesswire.com reported 2025-02-25 that NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.
Analysts’ Opinion of ITCI
Many brokerage firms have already submitted their reports for ITCI stocks, with Mizuho repeating the rating for ITCI by listing it as a “Neutral.” The predicted price for ITCI in the upcoming period, according to Mizuho is $132 based on the research report published on February 24, 2025 of the current year 2025.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $132, previously predicting the price at $119. The rating they have provided for ITCI stocks is “Hold” according to the report published on January 31st, 2025.
Piper Sandler gave a rating of “Overweight” to ITCI, setting the target price at $92 in the report published on September 06th of the previous year.
ITCI Trading at 5.13% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.04% of gains for the given period.
Volatility was left at 0.21%, however, over the last 30 days, the volatility rate increased by 0.12%, as shares surge +2.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +57.10% upper at present.
During the last 5 trading sessions, ITCI rose by +0.21%, which changed the moving average for the period of 200-days by +100.34% in comparison to the 20-day moving average, which settled at $130.31. In addition, Intra-Cellular Therapies Inc saw 57.48% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITCI starting from ALEXANDRIA VENTURE INVESTMENTS, who proposed sale 20,000 shares at the price of $131.42 back on Mar 18 ’25. After this action, ALEXANDRIA VENTURE INVESTMENTS now owns shares of Intra-Cellular Therapies Inc, valued at $2,628,450 using the latest closing price.
ALEXANDRIA VENTURE INVESTMENTS, the Director of Intra-Cellular Therapies Inc, proposed sale 11,750 shares at $131.43 during a trade that took place back on Mar 17 ’25, which means that ALEXANDRIA VENTURE INVESTMENTS is holding shares at $1,544,292 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.92 for the gross margin
The net margin for Intra-Cellular Therapies Inc stands at -0.11. The total capital return value is set at -0.1. Equity return is now at value -8.58, with -7.13 for asset returns.
Based on Intra-Cellular Therapies Inc (ITCI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -4.31.
Currently, EBITDA for the company is -116.72 million with net debt to EBITDA at 2.49. When we switch over and look at the enterprise to sales, we see a ratio of 20.12. The receivables turnover for the company is 4.09for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.36.
Conclusion
In a nutshell, Intra-Cellular Therapies Inc (ITCI) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
